Mira Pharmaceuticals (MIRA) Debt to Equity (2022 - 2023)
Mira Pharmaceuticals (MIRA) posted Debt to Equity of $1.51 for Q2 2023, up 775.14% sequentially from -$0.22 in Q4 2022.
Mira Pharmaceuticals (MIRA) Debt to Equity (2022 - 2023) Analysis & Trends
Mira Pharmaceuticals (MIRA) has 2 years of Debt to Equity data on file, last reported at $1.51 in Q2 2023.
- Quarterly Debt to Equity changed N/A year-over-year to $1.51 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $1.51 (changed N/A YoY) and the FY2022 annual result came in at -$0.22, changed N/A from the prior year.
- Debt to Equity grew to $1.51 in Q2 2023 per MIRA's latest filing, from -$0.22 in the prior quarter.
- The five-year high for Debt to Equity was $1.51 in Q2 2023, with the low at -$0.22 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 1.39 |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 0.68 |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | -9.70 |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 1.07 |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 6.24 |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 0.94 |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 0.72 |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Mira Pharmaceuticals | 22.51 Mn | 11.48 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 1.51 |
| Dec 31, 2022 | -0.22 |